Abstract
The rapidly expanding knowledge of the pathogenesis of a variety of forms of cancer at the molecular level is now providing new targets for drug discovery and development. This has enabled us to successfully develop rationally designed therapies for cancer patients, and the results of their clinical evaluation are now becoming available. The optimal clinical development of target-based anticancer drugs will require fundamental changes to the way trials are designed, outcome is evaluated, and patients are selected to receive therapy. A thorough knowledge of what is accomplished so far is the cornerstone to optimally develop and implement these new strategies.
Keywords: targeted therapy, egfr, her2, vegfr
Current Cancer Therapy Reviews
Title: Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer
Volume: 1 Issue: 1
Author(s): Antonio Jimeno and Hernán Cortes-Funes
Affiliation:
Keywords: targeted therapy, egfr, her2, vegfr
Abstract: The rapidly expanding knowledge of the pathogenesis of a variety of forms of cancer at the molecular level is now providing new targets for drug discovery and development. This has enabled us to successfully develop rationally designed therapies for cancer patients, and the results of their clinical evaluation are now becoming available. The optimal clinical development of target-based anticancer drugs will require fundamental changes to the way trials are designed, outcome is evaluated, and patients are selected to receive therapy. A thorough knowledge of what is accomplished so far is the cornerstone to optimally develop and implement these new strategies.
Export Options
About this article
Cite this article as:
Jimeno Antonio and Cortes-Funes Hernán, Membrane Receptor and Antiangiogenic Targeted Therapies in the Treatment of Cancer, Current Cancer Therapy Reviews 2005; 1 (1) . https://dx.doi.org/10.2174/1573394052952519
DOI https://dx.doi.org/10.2174/1573394052952519 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Rapamycin-loaded Immunoliposomes Functionalized with Trastuzumab: A Strategy to Enhance Cytotoxicity to HER2-positive Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Interactions of Cisplatin with non-DNA Targets and their Influence on Anticancer Activity and Drug Toxicity: The Complex World of the Platinum Complex
Current Cancer Drug Targets Patent Selections:
Recent Patents on Inflammation & Allergy Drug Discovery Flavonoid-Based Cancer Therapy: An Updated Review
Anti-Cancer Agents in Medicinal Chemistry A New Synthetic Spiroketal: Studies on Antitumor Activity on Murine Melanoma Model In Vivo and Mechanism of Action In Vitro
Anti-Cancer Agents in Medicinal Chemistry Rational Design and Development of Colon-Specific Prodrugs
Current Topics in Medicinal Chemistry ADAM-Integrin Interactions: Potential Integrin Regulated Ectodomain Shedding Activity
Current Pharmaceutical Design Polymer Drug Conjugates: Recent Advancements in Various Diseases
Current Pharmaceutical Design UBE2L6 is Involved in Cisplatin Resistance by Regulating the Transcription of ABCB6
Anti-Cancer Agents in Medicinal Chemistry A3 Receptor Ligands: Past, Present and Future Trends
Current Topics in Medicinal Chemistry Activin Receptor Signaling: A Potential Therapeutic Target for Osteoporosis
Current Molecular Pharmacology Antineoplastic Action of Growth Hormone-Releasing Hormone (GHRH) Antagonists
Recent Patents on Anti-Cancer Drug Discovery Vitamin E - Occurrence, Biosynthesis by Plants and Functions in Human Nutrition
Mini-Reviews in Medicinal Chemistry The Expression of Dopamine Receptors Gene and their Potential Role in Targeting Breast Cancer Cells with Selective Agonist and Antagonist Drugs. Could it be the Novel Insight to Therapy?
Current Drug Discovery Technologies Is there U-turn from Insulin Back to Pills in Diabetes?
Current Vascular Pharmacology The Antitumoral Mode of Action of Imiquimod and Other Imidazoquinolines
Current Medicinal Chemistry In vivo Near-infrared Fluorescence Tumor Imaging Using DiR-loaded Nanocarriers
Current Drug Delivery Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers Synthesis and Antimicrobial Activity of Some Novel Substituted 3-(Thiophen-2-yl)pyrazole-based Heterocycles
Letters in Drug Design & Discovery Pre-Clinical and Clinical Aspects of Peptide-based Vaccine Against Human Solid Tumors
Recent Patents on Biotechnology